Large Scale Study Shows HPV Testing Reduces Cervical Cancer Deaths

<< Back to Articles

Large Scale Study Shows HPV Testing Reduces Cervical Cancer Deaths

A study published in the April 2 issue of the New England Journal of Medicine (NEJM) found that HPV testing is the most effective way to reduce the incidence of cervical cancer when compared to either Pap testing or visual inspection with acetic acid (VIA).

The study is the largest trial to date of HPV testing against other methods of cervical cancer prevention. QIAGEN’s digene HPV Test (also known as the Hybrid Capture 2 HPV DNA test) was the screening test used in the trial to detect cancer-causing types of HPV. Cervical cancer screening tools were evaluated by the World Health Organization’s International Agency for Research on Cancer (IARC) in 130,000 women in India over eight years. Funding was provided by the Bill & Melinda Gates Foundation.

The study found that “a single round of HPV testing significantly reduces the numbers of advanced cervical cancers and deaths,” Read the full study here.

The study in the NEJM was accompanied by an editorial from the National Cancer Institute, stating “the implications of the findings of this trial are immediate and global: international experts in cervical-cancer prevention should now adapt HPV testing for widespread implementation.” Read the NCI editorial here.

Following the landmark publication, QIAGEN – the developer of the HPV testing technology used in the study - announced a commitment to donate 1 million HPV tests to expand access for women in developing countries to the highest quality cervical cancer screening methods. HPV tests will be donated over a five year period and directed among the world’s poorest countries as determined by national income and gross national income. Worldwide, cervical cancer claims nearly 300,000 lives every year, with 80 percent of deaths occurring in developing countries.

 


Read global media coverage of the study findings: